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enhancing the growth of altered cholangiocytes and leading to
increased CCa susceptibility [8,9].
These case reports suggest a need for prospective follow-up of
patients withMDR3mutations, in order to identify the CCa risk. It
would probably also be interesting to look for an MDR3 mutation
in young patients with CCa, especially if there exists a familial
history of CCa or biliary disease.
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Non-alcoholic fatty liver disease (NAFLD) is a burgeoning health
problem that affects one-third of adults and an increasing num-
ber of children in developed countries [1]. It was previously
reported that various therapeutic regimens can be adopted for
NAFLD [2], including weight loss agents, bariatric surgery, insu-
lin-sensitizing agents, lipid-lowering agents, antioxidants, and
other novel compounds. However, there is no consensus on its
treatment. Both lifestyle therapy and pharmacotherapy have lim-
itations due to poor compliance and side effects. Therefore, new
therapeutic approaches to managing NAFLD are urgently needed.
We read with interest the study by Parker et al. [3]. This is the
ﬁrst meta-analysis to investigate the effect of omega-3 polyunsat-
urated fatty acid (PUFA) on liver fat in humans. The authors found
that omega-3 PUFA could decrease liver fat and that beneﬁts were
seen with a consumption of >0.83 g/day. The results are instruc-
tive for the therapeutic regimen of NAFLD; however, we have
some concerns over the optimal dose mentioned in the article.Given the complications of NAFLD, especially cardiovascular
disease (CVD), the optimal dose of omega-3 PUFA should be
much higher than 0.83 g/day. Targher et al. revealed a strong
association between NAFLD and CVD risk by reviewing accumu-
lating clinical evidence [4]. Previous evidence suggests that CVD
dictates the outcome in patients with NAFLD more frequently
and to a greater extent than does the progression of liver disease,
and CVD is the most important cause of death in NAFLD patients
[5]. On the other hand, many investigators have demonstrated
that omega-3 PUFA could prevent CVD [6]. In a large-scale inter-
vention trial of secondary prevention after myocardial infarction,
GISSI-Prevenzione investigators identiﬁed a substantial reduction
in all-cause and cardiovascular mortality with 1 g per day of n-3
PUFA supplementation [7]. In addition, McKenney et al. recom-
mend n-3 PUFA supplementation at a dose of 2–4 g per day to
patients with high triglyceride concentrations [8]. At present,
Saravanan et al. found that omega-3 PUFA could act as beneﬁcial
pleiotropic agents to prevent CVD, by conducting a review of
numerous clinical trials [9]. As ﬁsh is rich in omega-3 PUFA, the12 vol. 57 j 467–477
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Table 1. Risk of side effects from ingestion of omega-3 PUFA [6].
Gastrointestinal upset Clinical bleeding Fishy aftertaste Worsening glycemiaa Rise in LDL-Cb
Up to 1 g/d Very low Very low Low Very low Very low
1 to 3 g/d Moderate Very low Moderate Low Moderate
>3 g/d Moderate Low Likely Moderate Likely
LDL-C, low density lipoprotein–cholesterol.
aUsually only in patients with impaired glucose tolerance and diabetes.
bUsually only in patients with hypertriglyceridemia.
JOURNAL OF HEPATOLOGYAmerican Heart Association recommends at least two ﬁsh meals
per week to healthy people, and a supplemental therapy with 1 g
of omega-3 PUFA per day to those with myocardial infarction [6].
Omega-3 PUFA may treat NAFLD and CVD simultaneously, killing
two birds with one stone [10].
In this review, the average dose of omega-3 PUFA was 4 g/day
(range: 0.8–13.7 g/day), and the authors found no reports of
adverse effects of omega-3 PUFA supplementation in the studies
reviewed. We should be cautious about this conclusion, because
side effects of omega-3 PUFA supplementation do exist (Table 1).
We agree to adopt therapeutic regimen for NAFLD. However,
we sincerely hope that the researchers take the CVD risk and
the side effects of omega-3 PUFA in NAFLD into account when
they determine the optimal dose of omega-3 PUFA. Because
omega-3 PUFA could treat NAFLD and CVD, it is promising to con-
sider that the optimal dose of omega-3 PUFA could be applied for
NAFLD associated risk of CVD. Of course, the hypothesis needs to
be validated by well-designed randomized controlled trials.
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We read with interest the letter by Drs. Li and Chen regarding our
systematic review and meta-analysis of omega-3 supplementa-
tion in non-alcoholic fatty liver disease (NAFLD) [1]. We showed
that, when compared with a control therapy, dietary omega-3
supplementation led to beneﬁcial changes in liver fat in adults.
On the basis of the pooled results of studies, which employed
omega-3 supplementation of 0.83–13.7 g per day, we observed
a statistically signiﬁcant beneﬁt on liver fat, which persisted even
when only randomized controlled trials were examined.
Due to the strong association between NAFLD and cardiovas-
cular disease (CVD), the importance of CVD to mortality in
patients with NAFLD, and the beneﬁt of omega-3 supplementa-
tion in CVD risk reduction, Li and Chen suggest that the optimaldose of omega-3 should be higher than 0.83 g per day. We point
out that pooling of data by meta-analysis is a useful tool for
objectively evaluating the consensus of a therapy such as
omega-3 supplementation (vs. a suitable control). However, the
heterogeneity and relative paucity of data entail that these
results should not be used to inform clinical recommendations
on issues such as optimal dosage in NAFLD Using the data from
trials in cardiovascular disease of omega-3 supplementation to
recommend a particular omega-3 dose for NAFLD would be an
inference, not supported by the NAFLD data we have presented.
As stated in our manuscript, more data from randomized con-
trolled trials are required for this. While our meta-analysis
substantiates the efﬁcacy of omega-3 supplementation for mod-
ifying liver fat per se, the choice of dose in an individual with2 vol. 57 j 467–477 469
